How does TP53 (p53) mutation status influence treatment selection for a patient with relapsed multiple myeloma after an autologous stem‑cell transplant?

TP53 Mutation Status in Relapsed Multiple Myeloma After Autologous Transplant

Patients with TP53 (del17p or mutation) relapsed myeloma after autologous transplant require aggressive triplet or quadruplet regimens combining second-generation proteasome inhibitors and monoclonal antibodies, as these combinations have demonstrated improved outcomes specifically in this high-risk population. 1

Risk Stratification at Relapse

Restaging with FISH testing for TP53 aberrations is mandatory at relapse, as the frequency of TP53 alterations increases from 5% at diagnosis to 75% at late relapses, and acquisition of new TP53 alterations dramatically worsens prognosis. 2, 3, 4

• TP53 "double-hit" status (both deletion and mutation, or single mutation with VAF ≥40%, or >1 mutation) confers the worst outcomes with median PFS of 8 months and OS of 21 months post-transplant, compared to 28 and 56 months respectively in TP53-normal patients. 5, 3
• Single TP53 alterations at subclonal levels have intermediate impact, but evolution to double-hit at relapse is common and associated with rapid progression. 3

Preferred Treatment Regimens for TP53-Mutated Relapse

First-Line Relapse Options

Daratumumab-based triplets are the cornerstone of therapy for TP53-mutated relapsed myeloma, as meta-analysis data specifically demonstrate that combined therapy with second-generation proteasome inhibitors, monoclonal antibodies, and immunomodulatory drugs improves outcomes in del(17p) patients. 1

Specific regimen selection depends on prior therapy exposure:

• If lenalidomide-refractory: Daratumumab + bortezomib + dexamethasone (DVd) or daratumumab + carfilzomib + dexamethasone (DKd) are preferred, with DKd achieving 84% ORR and 74% 12-month PFS in dual-refractory disease. 6, 7

• If bortezomib-refractory: Carfilzomib + pomalidomide + dexamethasone (KPd) is the regimen of choice. 6

• If dual-refractory (lenalidomide + bortezomib): Daratumumab + carfilzomib + dexamethasone (DKd) or isatuximab + carfilzomib + dexamethasone (Isa-Kd) are recommended, as both demonstrated superior PFS in randomized trials. 6, 7

Alternative Triplet Regimens

When daratumumab-based therapy is unavailable or previously used, the following triplets have demonstrated efficacy (though not specifically tested in TP53-mutated cohorts):

• Carfilzomib + lenalidomide + dexamethasone (KRd) 1, 6, 1
• Elotuzumab + lenalidomide + dexamethasone (ERd) 2
• Ixazomib + lenalidomide + dexamethasone (IRd) 2

Role of Salvage Transplantation

Repeat autologous stem cell transplantation should be considered at first relapse only if the initial post-transplant remission duration was ≥18 months, though outcomes remain poor in TP53-mutated disease with median post-salvage PFS of only 8 months. 1, 5

• The 18-month threshold is critical; patients relapsing earlier have median OS <6 months with salvage transplant. 1
• In TP53-mutated patients who achieved prolonged initial remission (>18 months), salvage ASCT may be offered as part of a sequential strategy before novel agent combinations. 2

Second and Subsequent Relapses

For TP53-mutated patients progressing after first relapse therapy, quadruplet regimens or addition of novel agents to triplet backbones is required, as outcomes with standard doublets are dismal. 6, 2

Specific options include:

• Selinexor + bortezomib + dexamethasone 6
• Panobinostat added to proteasome inhibitor-containing regimens 2, 6, 2
• Bendamustine-based regimens 2, 6, 2
• Intensive chemotherapy (VDT-PACE) for aggressive relapse or extramedullary disease, followed by consolidation ASCT if feasible 2

Allogeneic stem cell transplantation should be considered for young TP53-mutated patients with suitable donors, preferably in the context of clinical trials, as this represents the only potentially curative approach. 8, 6

Critical Treatment Principles

• Avoid lenalidomide monotherapy or doublet regimens in TP53-mutated disease; proteasome inhibitor-based triplets are mandatory. 1
• Do not delay switching therapy if relapse occurs within 6 months of completing prior treatment, as these patients are refractory and require immediate regimen change. 1
• Continuous therapy until progression is essential; treatment-free intervals are not appropriate in TP53-mutated disease given the aggressive biology. 6

Supportive Care Requirements

• Thromboprophylaxis with full-dose aspirin (81-325 mg daily) is mandatory for all immunomodulatory drug-containing regimens. 6, 9
• Herpes zoster prophylaxis with acyclovir 400 mg twice daily or valacyclovir 500 mg daily is required for all proteasome inhibitor-based therapy. 6, 9
• Subcutaneous bortezomib administered weekly reduces peripheral neuropathy while preserving efficacy compared to twice-weekly intravenous dosing. 6, 9

Prognosis and Counseling

Patients and families must be counseled that TP53-mutated relapsed myeloma after autologous transplant carries a median overall survival of 21 months despite aggressive therapy, and that clinical trial enrollment should be strongly encouraged. 5

• The presence of relapsed disease at the time of transplant independently predicts earlier progression (HR 2.0). 1
• TP53 mutation status independently predicts progression with HR 3.4 compared to TP53-normal disease. 5
• Novel therapeutic approaches targeting the p53 pathway (MDM2 inhibitors, p53 reactivators) are under investigation but not yet standard of care. 4, 10